Oral GnRH Antagonists in Combination with Estradiol and Norethindrone Acetate for Pain Relief Associated with Endometriosis: A Review of Evidence of a Novel Class of Hormonal Agents

References

• Zondervan KT, Becker CM, Missmer SA. Endometriosis. N Engl J Med. 2020;382:1244–1256. doi:10.1056/NEJMra1810764
   PubMed Web of Science ®Google Scholar
• Shafrir AL, Farland LV, Shah DK, et al. Risk for and consequences of endometriosis: a critical epidemiologic review. Best Pract Res Clin Obstet Gynaecol. 2018;51:1–15. doi:10.1016/j.bpobgyn.2018.06.001
   PubMed Web of Science ®Google Scholar
• Prescott J, Farland LV, Tobias DK, et al. A prospective cohort study of endometriosis and subsequent risk of infertility. Hum Reprod. 2016;31(7):1475–1482. doi:10.1093/humrep/dew085
   PubMed Web of Science ®Google Scholar
• Taylor HS, Kotlyar AM, Flores VA. Endometriosis is a chronic systemic disease: clinical challenges and novel innovations. Lancet. 2021;397(10276):839–852. doi:10.1016/S0140-6736(21)00389-5
   PubMed Web of Science ®Google Scholar
• Greene R, Stratton P, Cleary SD, Ballweg ML, Sinaii N. Diagnostic experience among 4334 women reporting surgically diagnosed endometriosis. Fertil Steril. 2009;91:32–39. doi:10.1016/j.fertnstert.2007.11.020
   PubMed Web of Science ®Google Scholar
• Nnoaham KE, Hummelshoj L, Webster P, et al. Impact of endometriosis on quality of life and work productivity: a multicenter study across ten countries. Fertil Steril. 2011;96(2):366–373.e8. doi:10.1016/j.fertnstert.2011.05.090
   PubMed Web of Science ®Google Scholar
• Horne AW, Missmer SA. Pathophysiology, diagnosis, and management of endometriosis. BMJ. 2022;14(379):e070750. doi:10.1136/bmj-2022-070750
   Google Scholar
• Chapron C, Marcellin L, Borghese B, Santulli P. Rethinking mechanisms, diagnosis and management of endometriosis. Nat Rev Endocrinol. 2019;15(11):666–682. doi:10.1038/s41574-019-0245-z
   PubMed Web of Science ®Google Scholar
• Becker CM, Gattrell WT, Gude K, Singh SS. Reevaluating response and failure of medical treatment of endometriosis: a systematic review. Fertil Steril. 2017;108(1):125. doi:10.1016/j.fertnstert.2017.05.004
   PubMed Web of Science ®Google Scholar
• Vercellini P, Barbara G, Abbiati A, Somigliana E, Viganò P, Fedele L. Repetitive surgery for recurrent symptomatic endometriosis: what to do? Eur J Obstet Gynecol Reprod Biol. 2009;146:15–21. doi:10.1016/j.ejogrb.2009.05.007
   PubMed Web of Science ®Google Scholar
• de Ziegler D, Pirtea P, Carbonnel M, et al. Assisted reproduction in endometriosis. Best Pract Res Clin Endocrinol Metab. 2019;33(1):47–59. doi:10.1016/j.beem.2018.10.001
   PubMed Web of Science ®Google Scholar
• Lier MCI, Malik RF, Ket JCF, Lambalk CB, Brosens IA, Mijatovic V. Spontaneous hemoperitoneum in pregnancy (SHiP) and endometriosis - A systematic review of the recent literature. Eur J Obstet Gynecol Reprod Biol. 2017;219:57–65. doi:10.1016/j.ejogrb.2017.10.012
   PubMed Web of Science ®Google Scholar
• Bedaiwy MA, Alfaraj S, Yong P, Casper R. New developments in the medical treatment of endometriosis. Fertil Steril. 2017;107(3):555–565. doi:10.1016/j.fertnstert.2016.12.025
   PubMed Web of Science ®Google Scholar
• Barbara G, Buggio L, Facchin F, Vercellini P. Medical treatment for endometriosis: tolerability, quality of life and adherence. Front Glob Women’s Health. 2021;27(2):729601. doi:10.3389/fgwh.2021.729601
   Google Scholar
• Vercellini P, Buggio L, Berlanda N, Barbara G, Somigliana E, Bosari S. Estrogen-progestins and progestins for the management of endometriosis. Fertil Steril. 2016;106:1552–1571.e2. doi:10.1016/j.fertnstert.2016.10.022
   PubMed Web of Science ®Google Scholar
• Donnez J, Dolmans MM. Endometriosis and medical therapy: from progestogens to progesterone resistance to GnRH antagonists: a review. J Clin Med. 2021;10:1085. doi:10.3390/jcm10051085
   PubMed Web of Science ®Google Scholar
• Becker CM, Bokor A, Heikinheimo O, et al. ESHRE guideline: endometriosis. Hum Reprod Open. 2022;2022(2):hoac009. doi:10.1093/hropen/hoac009
   PubMedGoogle Scholar
• Practice Committee of the American Society for Reproductive Medicine. Treatment of pelvic pain associated with endometriosis: a committee opinion. Fertil Steril. 2014;101:927–935. doi:10.1016/j.fertnstert.2014.02.012
   PubMed Web of Science ®Google Scholar
• Vercellini P, Buggio L, Frattaruolo MP, Borghi A, Dridi D, Somigliana E. Medical treatment of endometriosis-related pain. Best Pract Res Clin Obstet Gynaecol. 2018;51:68–91. doi:10.1016/j.bpobgyn.2018.01.015
   PubMed Web of Science ®Google Scholar
• Ailawadi RK, Jobanputra S, Kataria M, Gurates B, Bulun SE. Treatment of endometriosis and chronic pelvic pain with letrozole and norethindrone acetate: a pilot study. Fertil Steril. 2004;81:290–296. doi:10.1016/j.fertnstert.2003.09.029
   PubMed Web of Science ®Google Scholar
• Ferrero S, Venturini PL, Ragni N, Camerini G, Remorgida V. Pharmacological treatment of endometriosis: experience with aromatase inhibitors. Drugs. 2009;69:943–952. doi:10.2165/00003495-200969080-00001
   PubMed Web of Science ®Google Scholar
• Ng J, Chwalisz K, Carter DC, Klein CE. Dose-dependent suppression of gonadotropins and ovarian hormones by elagolix in healthy premenopausal women. J Clin Endocrinol Metab. 2017;102:1683–1691. doi:10.1210/jc.2016-3845
   PubMed Web of Science ®Google Scholar
• Osuga Y, Enya K, Kudou K, et al. Oral gonadotropin-releasing hormone antagonist relugolix compared with leuprorelin injections for uterine leiomyomas: a randomized controlled trial. Obstet Gynecol. 2019;133:423–433. doi:10.1097/AOG.0000000000003141
   PubMed Web of Science ®Google Scholar
• Donnez J, Dolmans MM. GnRH antagonists with or without add-back therapy: a new alternative in the management of endometriosis? Int J Mol Sci. 2021;22(21):11342. doi:10.3390/ijms222111342
   PubMed Web of Science ®Google Scholar
• Donnez J, Taylor RN, Taylor HS. Partial suppression of estradiol: a new strategy in endometriosis management? Fertil. Steril. 2017;107:568–570. doi:10.1016/j.fertnstert.2017.01.013
   PubMed Web of Science ®Google Scholar
• Mikuš M, Šprem Goldštajn M, Laganà AS, Vukorepa F, Clinical Efficacy ĆM. Pharmacokinetics, and Safety of the available medical options in the treatment of endometriosis-related pelvic pain: a scoping review. Pharmaceuticals. 2023;16(9):1315. doi:10.3390/ph16091315
   Web of Science ®Google Scholar
• Zajec V, Mikuš M, Vitale SG, et al. Current status and challenges of drug development for hormonal treatment of endometriosis: a systematic review of randomized control trials. Gynecol Endocrinol. 2022;38(9):713–720.
   PubMed Web of Science ®Google Scholar
• Taylor HS, Dun EC, Chwalisz K. Clinical evaluation of the oral gonadotropin-releasing hormone-antagonist elagolix for the management of endometriosis-associated pain. Pain Manag. 2019;9:497–515. doi:10.2217/pmt-2019-0010
   PubMed Web of Science ®Google Scholar
• Carr B, Dmowski WP, O’Brien C, et al. Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density. Reprod Sci. 2014;21(11):1341–1351. doi:10.1177/1933719114549848
   PubMed Web of Science ®Google Scholar
• Taylor HS, Giudice LC, Lessey BA, et al. Treatment of endometriosis-associated pain with elagolix, an Oral GnRH antagonist. N Engl J Med. 2017;377(1):28–40. doi:10.1056/NEJMoa1700089
   PubMed Web of Science ®Google Scholar
• Surrey E, Taylor HS, Giudice L, et al. Long-term outcomes of elagolix in women with endometriosis: results from two extension studies. Obstet Gynecol. 2018;132(1):147–160. doi:10.1097/AOG.0000000000002675
   PubMed Web of Science ®Google Scholar
• Leyland N, Estes SJ, Lessey BA, Advincula AP, Taylor HS, Clinician’s A. Guide to the Treatment of Endometriosis with Elagolix. J Womens Health. 2021;30(4):569–578. doi:10.1089/jwh.2019.8096
   PubMed Web of Science ®Google Scholar
• Markham A. Relugolix: first Global Approval. Drugs. 2019;79(6):675–679. doi:10.1007/s40265-019-01105-0
   PubMed Web of Science ®Google Scholar
• Osuga Y, Seki Y, Tanimoto M, Kusumoto T, Kudou K, Terakawa N. Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose-response manner: a randomized, double-blind, placebo-controlled study. Fertil Steril. 2021;115(2):397–405. doi:10.1016/j.fertnstert.2020.07.055
   PubMed Web of Science ®Google Scholar
• Osuga Y, Seki Y, Tanimoto M, Kusumoto T, Kudou K, Terakawa N. Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: phase 2 safety and efficacy 24-week results. BMC Womens Health. 2021;21(1):250. doi:10.1186/s12905-021-01393-3
   PubMed Web of Science ®Google Scholar
• Harada T, Osuga Y, Suzuki Y, Fujisawa M, Fukui M, Kitawaki J. Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain compared with leuprorelin in Japanese women: a phase 3, randomized, double-blind, noninferiority study. Fertil Steril. 2022;117(3):583–592. doi:10.1016/j.fertnstert.2021.11.013
   PubMed Web of Science ®Google Scholar
• Giudice LC, As-Sanie S, Arjona Ferreira JC, et al. Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2). Lancet. 2022;399(10343):2267–2279. doi:10.1016/S0140-6736(22)00622-5
   PubMed Web of Science ®Google Scholar
• Donnez J, Taylor HS, Taylor RN, et al. Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin- releasing hormone-antagonist: a randomized clinical trial. Fertil Steril. 2020;114(1):44–55. doi:10.1016/j.fertnstert.2020.02.114
   PubMed Web of Science ®Google Scholar
• Buggio L, Dridi D, Barbara G, et al. Novel pharmacological therapies for the treatment of endometriosis. Expert Rev Clin Pharmacol. 2022;15(9):1039–1052. doi:10.1080/17512433.2022.2117155
   PubMed Web of Science ®Google Scholar
• Vercellini P, Viganò P, Barbara G, et al. Elagolix for endometriosis: all that glitters is not gold. Hum Reprod. 2019;34(2):193–199. doi:10.1093/humrep/dey368
   PubMed Web of Science ®Google Scholar
• As-Sanie S, Giudice L, Abrao MS, et al. O-132 sustained efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: SPIRIT 52-week data. Hum Reprod. 2021;36(suppl 1):deab126.057. doi:10.1093/humrep/deab126.057
   Google Scholar
• Saraswat L, Bhattacharya S. Relugolix combination therapy for endometriosis pain. Lancet. 2022;399(10343):2244–2245. doi:10.1016/S0140-6736(22)00663-8
   PubMed Web of Science ®Google Scholar
• Myovant Sciences GmbH and Pfizer Inc. Cost and support for myfembree: cost guide; 2003. Available from: https://www.myfembree.com/cost-and-support/#download-cost-guide. Accessed August 6, 2023.
   Google Scholar
• Wang ST, Johnson SJ, Mitchell D, Soliman AM, Vora JB, Agarwal SK. Cost-effectiveness of elagolix versus leuprolide acetate for treating moderate-to-severe endometriosis pain in the USA. J Comp Eff Res. 2019;8(5):337–355. doi:10.2217/cer-2018-0124
   PubMed Web of Science ®Google Scholar